Edumed - Company finances
|
EUR
|
2024
From: 2024-08-06
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 174,883 | 23,900 |
| Profit before tax | 45,018 | -4,726 |
| Net profit | 45,018 | -4,726 |
| Equity | 45,118 | 40,392 |
| Liabilities | 110,800 | 22,622 |
| Non-current assets | 0 | 42,163 |
| Current assets | 155,918 | 20,851 |
| Total assets | 155,918 | 63,014 |
|
Taxes paid
|
||
| STI taxes | 10,491 | 26,196 |
|
Financial indicators
|
||
| Revenue change y/y | - | -86.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 28.9% | -7.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 99.8% | -11.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 25.7% | -19.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 25.7% | -19.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.5 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Edumed - Social security debts
The company had no debts to Sodra
Edumed - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Edumed, MB (code 306966785) is a Lithuanian small partnership operating in the wholesale of pharmaceutical and medical goods. In 2025, the latest financial year, the company generated revenue of €23.9K and recorded a net loss of €4.7K, resulting in a net margin of -19.8%. Revenue declined by 86.3% year on year, indicating a marked contraction in business volume. The previous reported year, 2024, covered 147 days and showed revenue of €174.9K with net profit of €45.0K, so the move from profit to loss in 2025 reflects a clear weakening in performance. At the end of 2025, total assets stood at €63.0K, equity at €40.4K, and liabilities at €22.6K. The equity ratio was 64.1% and debt-to-equity 0.56, suggesting a moderate balance sheet leverage position. Return on equity was -11.7% and return on assets -7.5%, while asset turnover was 0.38x, consistent with limited revenue generation relative to the asset base.